ZITHROMAX (Azithromycin) Dosage & Rx Info, Uses - MPR
ZITHROMAX prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and ZITHROMAXside effects.
C. Difficile Prevention Therapy Zinplava Discontinued - MPR
Jan 7, 2025 · Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.. Zinplava, a …
Prednisone Prescription & Dosage Information - MPR
Prednisone Tablets are indicated for the following conditions: Endocrine Disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic ...
The MPR Drug Reference Database for Healthcare Practitioners
View our rich drug database that contains concise drug information on more than 4,000 drugs and provides indication, dose, contraindications, precautions, interactions, adverse reactions ...
Famotidine Prescription & Dosage Information - MPR
Famotidine prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and Famotidineside effects.
Experts Weigh in on the Best Diets for 2025 - MPR
Jan 3, 2025 · An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined the evidence behind 38 diets.
Ibuprofen Prescription & Dosage Information - MPR
Ibuprofen prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and Ibuprofenside effects.
Blood Glucose Meter Compatibility with Test Strips - MPR
Nov 19, 2012 · BLOOD GLUCOSE METER COMPATIBILITY WITH TEST STRIPS; Company Meters Test Strips; ABBOTT LABS diabetescare.abbott: FreeStyle Freedom Lite: FreeStyle …
Hydrocodone/acetaminophen (325mg) - MPR
Hydrocodone bitartrate, acetaminophen; 5mg/325mg, 7.5mg/325mg, 10mg/325mg; scored tabs. Use lowest effective dose for shortest duration. Individualize. 5mg/325mg: 1–2 tabs every …
FDA Drug Approval Decisions Expected in January 2025 - MPR
Dec 6, 2024 · The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.